Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)
Brief Summary: The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).


Options:
A: Arm Label: Rotational arm; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Drug: Everolimus | Arm Label: Sequential arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib, Drug: Everolimus | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Rotational arm, Sequential arm | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Rotational arm, Sequential arm
B: Arm Label: ccRCC molecular subgroup 1: 1A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 1: 1B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 4: 4A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 4: 4B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 2: 2C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Arm Label: ccRCC molecular subgroup 2: 2B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1A, ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4A, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C
C: Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Behavioral: Quality of Life Assessment | Arm Label: Temsirolimus; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Behavioral: Quality of Life Assessment, Drug: Benadryl | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Temsirolimus | Intervention Type: BEHAVIORAL; Name: Quality of Life Assessment; Assigned to Arm(s): Pazopanib, Temsirolimus | Intervention Type: DRUG; Name: Benadryl; Assigned to Arm(s): Temsirolimus
D: Arm Label: Lenvatinib 18 mg plus Everolimus 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Lenvatinib 20 mg plus Pembrolizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Arm Label: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg, Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib 50 mg

Answer: D